Related Experiment Videos
Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction
1Department of Medicine, University of Auckland School of Medicine, New Zealand.
Insights
Captopril significantly improved cardiac function in patients post-myocardial infarction by reducing left ventricular end-systolic volume and increasing ejection fraction, unlike frusemide or placebo.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Left ventricular dysfunction is a common complication following myocardial infarction (MI).
- Early intervention aims to prevent adverse cardiac remodeling and heart failure.
- Angiotensin-converting enzyme inhibitors are explored for their potential benefits post-MI.
Purpose of the Study:
- To evaluate the effects of captopril on left ventricular remodeling and function after Q wave myocardial infarction.
- To compare captopril's efficacy against frusemide and placebo in patients with post-MI left ventricular dysfunction.
Main Methods:
- A randomized, double-blind trial involving 60 patients with left ventricular dysfunction (ejection fraction < 45%) one week post-MI.
- Patients received captopril (25 mg thrice daily), frusemide (40 mg daily), or placebo.
- Left ventricular volumes and ejection fraction were assessed using echocardiography and Simpson's rule at baseline and up to 12 months.
Main Results:
- Captopril significantly reduced left ventricular end-systolic volume index and increased stroke volume index and ejection fraction from one month onwards.
- In contrast, frusemide and placebo groups exhibited increased ventricular volumes, with unchanged stroke volume index and slightly reduced ejection fraction.
- Changes observed in the captopril group were statistically significant compared to the frusemide and placebo groups.
Conclusions:
- Captopril demonstrates significant benefits in preserving and improving left ventricular function in the early period after Q wave myocardial infarction.
- Captopril effectively counteracts adverse ventricular remodeling, unlike frusemide or placebo, in this patient population.
- These findings support the use of captopril for managing left ventricular dysfunction post-MI to improve cardiac outcomes.
Abstract:
In a randomised, double-blind trial 60 patients with left ventricular dysfunction (ejection fraction less than 45%) but without clinical evidence of heart failure 1 week after Q wave myocardial infarction were given captopril 25 mg thrice a day, frusemide 40 mg daily, or placebo. Left ventricular volumes were measured at baseline and at 1, 3, 6, 9, and 12 months with cross-sectional echocardiography and Simpson's rule analysis of standardised apical views. The captopril group showed no significant change in left ventricular end-diastolic volume index but left ventricular end-systolic volume index was significantly reduced and stroke volume index and ejection fraction were significantly increased from 1 month on. In contrast, the frusemide and placebo groups showed significant increases in ventricular volumes, with stroke volume index unchanged and ejection fraction slightly reduced. The changes in the captopril group were significantly different from those in the other groups.